[go: up one dir, main page]

EP0381075A3 - Method for treating addiction to a drug of abuse employing an ace inhibitor - Google Patents

Method for treating addiction to a drug of abuse employing an ace inhibitor Download PDF

Info

Publication number
EP0381075A3
EP0381075A3 EP19900101591 EP90101591A EP0381075A3 EP 0381075 A3 EP0381075 A3 EP 0381075A3 EP 19900101591 EP19900101591 EP 19900101591 EP 90101591 A EP90101591 A EP 90101591A EP 0381075 A3 EP0381075 A3 EP 0381075A3
Authority
EP
European Patent Office
Prior art keywords
drug
abuse
ace inhibitor
employing
treating addiction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900101591
Other languages
German (de)
French (fr)
Other versions
EP0381075A2 (en
Inventor
Zola P. Horovitz
Abraham Sudilovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of EP0381075A2 publication Critical patent/EP0381075A2/en
Publication of EP0381075A3 publication Critical patent/EP0381075A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method is provided for treating addiction to a drug of abuse such as nicotine, cocaine or diazepam, by inhibiting appetite or desire for such drug by administering an ACE inhibitor, such as captopril, fosinopril, zofenopril or SQ 29,852, alone or in combination with a calcium channel blocker such as diltiazem or nifedipine, over a prolonged period of treatment.
EP19900101591 1989-01-30 1990-01-26 Method for treating addiction to a drug of abuse employing an ace inhibitor Withdrawn EP0381075A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US303504 1989-01-30
US07/303,504 US5093129A (en) 1989-01-30 1989-01-30 Method for treating addiction to a drug of abuse employing an ace inhibitor

Publications (2)

Publication Number Publication Date
EP0381075A2 EP0381075A2 (en) 1990-08-08
EP0381075A3 true EP0381075A3 (en) 1992-12-09

Family

ID=23172420

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900101591 Withdrawn EP0381075A3 (en) 1989-01-30 1990-01-26 Method for treating addiction to a drug of abuse employing an ace inhibitor

Country Status (10)

Country Link
US (1) US5093129A (en)
EP (1) EP0381075A3 (en)
JP (1) JPH02235822A (en)
AU (1) AU630409B2 (en)
CA (1) CA2007524A1 (en)
HU (1) HUT53285A (en)
IE (1) IE900313L (en)
NZ (1) NZ232079A (en)
PT (1) PT92988A (en)
ZA (1) ZA90675B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007525A1 (en) * 1989-01-30 1990-07-30 Zola P. Horovitz Method for facilating dieting employing an ace inhibitor
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
CA2050042A1 (en) * 1990-09-17 1992-03-18 Zola P. Horovitz Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
TW197945B (en) * 1990-11-27 1993-01-11 Hoechst Ag
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
DE4426259A1 (en) * 1994-07-25 1996-02-15 Upmeyer Hans Juergen Medical use of angiotensin-converting enzyme inhibitor
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
WO2004075893A1 (en) * 2003-02-24 2004-09-10 Diakron Pharmaceuticals, Inc. Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker
PL227900B1 (en) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Pharmaceutical composition comprising an ACE inhibitor and a calcium channel blocker, a method for its preparation and the dosage unit comprising the composition
CN110507652A (en) * 2019-09-24 2019-11-29 中国医科大学 New use of the drug nifedipine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0321221A2 (en) * 1987-12-14 1989-06-21 E.R. Squibb & Sons, Inc. Method for preventing or treating anxiety employing an ace inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
US4460604A (en) * 1976-06-03 1984-07-17 The Upjohn Company 4-Amino-4-aryl-cyclohexanones
US4416871A (en) * 1978-07-10 1983-11-22 The United States Of America As Represented By The Department Of Health And Human Services Inhibition by peptides of tolerance to and physical dependence on morphine
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
NZ201997A (en) * 1981-09-25 1985-12-13 Wellcome Found Phosphorus-containing amides and pharmaceutical compositions
US4452790A (en) * 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4652641A (en) * 1984-06-26 1987-03-24 S. C. Mitri Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists
DE3610391A1 (en) * 1986-03-27 1987-10-08 Hoechst Ag COMPOUNDS WITH NOOTROPPER ACTION, THESE CONTAINERS AND THEIR USE IN THE TREATMENT AND PROPHYLAXIS OF COGNITIVE DYSFUNCTIONS
FR2607004B1 (en) * 1986-11-20 1990-06-01 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0321221A2 (en) * 1987-12-14 1989-06-21 E.R. Squibb & Sons, Inc. Method for preventing or treating anxiety employing an ace inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALCOHOL. CLIN. EXP. RES., vol. 12, no. 1, February 1988, pages 65-70; G. SPINOSA et al.: "Angiotensin converting enzyme inhibitors: Animal experiments suggest a new pharmacological treatment for alcohol abuse in humans" *
ALCOHOL. CLIN. EXP. RES., vol. 14, no. 1, February 1990, pages 92-99; T. LINGHAM et al.: "Angiotensin converting enzyme inhibitors reduce alcohol consumption: Some possible mechanisms and important conditions for its therapeutic use" *
CLIN. PHARMACOL. THER., vol. 50, no. 1, July 1991, pages 96-106; C.A. NARANJO et al.: "Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics" *
GIORNALE DI CLINICA MEDICA, vol. 66, nos. 11-12, 1986, pages 459-466, Bologna, IT; G. GERRA et al.: "Effetto del diclofenac sulla "opiate withdrawal syndrome"" *

Also Published As

Publication number Publication date
HU9000380D0 (en) 1990-03-28
EP0381075A2 (en) 1990-08-08
ZA90675B (en) 1990-10-31
NZ232079A (en) 1997-06-24
IE900313L (en) 1990-07-30
HUT53285A (en) 1990-10-28
JPH02235822A (en) 1990-09-18
AU4851190A (en) 1990-08-02
PT92988A (en) 1990-07-31
US5093129A (en) 1992-03-03
CA2007524A1 (en) 1990-07-30
AU630409B2 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
EP0381075A3 (en) Method for treating addiction to a drug of abuse employing an ace inhibitor
SG94343A1 (en) Inhibitors of romatase enzyme activity
IL112048A0 (en) Methods of inhibiting thrombin
TW371628B (en) Composition for treating condyloma acuminata
PH31263A (en) Methods of inhibiting vascular smooth muscle cell proliferation and restinosis.
AU2643288A (en) Pharmaceutical compositions
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
WO2001072309A3 (en) Treatment of cerebrovascular disease
AU2460900A (en) Shortened-chain polynucleotides and process for the preparation thereof
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
AU693833B2 (en) Products containing G-CSF and TNF binding protein
AU7579194A (en) Methods for inhibiting angiogenisis and angiogenic diseases
PH31325A (en) Methods of increasing thrombomodulin expression.
EP0321221A3 (en) Method for preventing or treating anxiety employing an ace inhibitor
EP1632248B8 (en) Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness
EP0400665A3 (en) Use of a calcium channel blocker for preventing or treating anxiety
GR3021813T3 (en) Method of treating alopecia
EP0381074A3 (en) Method for facilitating dieting employing an ace inhibitor
EP0344995A3 (en) Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor
HUT52698A (en) Process for producing pharmaceutical compositions for treating autoimmune leucoencephalomyelitis like diseases as sclerosis multiplex
EP0331803A3 (en) Medicament for inhibiting onset of or treating migraine headaches employing an ace inhibitor
EP0286802A3 (en) Use of ofloxacin in treating or preventing locally periodontal disease
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
EP1007050A4 (en) Method for treating substance abuse
GB9104806D0 (en) Method for preventing onset of or treating protein catabolism

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

K1C1 Correction of patent application (title page) published

Effective date: 19900808

17P Request for examination filed

Effective date: 19930601

17Q First examination report despatched

Effective date: 19930723

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940203